Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Montfermeil – page 208

3 423 clinical trials in Montfermeil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Montfermeil at a glance
3 423
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 423 trials in Montfermeil

Open in trial search

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of Vidutolimod and Cemiplimab for Adults with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Methotrexate, Dexamethasone, and Montelukast to Prevent Infusion Reactions in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Fecal Microbiota Transplantation for Patients with Axial Spondyloarthritis Resistant to Conventional Treatment

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Unicancer

Crohn's disease

Not recruiting

Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Phenylketonuria

Not recruiting

Study on the Long-Term Safety of PTC923 (Sepiapterin) for Patients with Phenylketonuria

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepiapterin
  • Sponsor:PTC Therapeutics Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma

Not recruiting

Study on the Effectiveness and Safety of Tisagenlecleucel for Adults with Hard-to-Treat or Returning Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Montfermeil

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on acute myocarditis treatment and cardiac arrhythmia management. Research includes evaluation of corticosteroid therapy for improving left ventricular function and investigating preventive measures for premature ventricular complexes.

  • Myocarditis Treatment Optimization
  • Cardiac Function Management
  • Giant Cell Arteritis Studies

These trials aim to enhance treatment outcomes for patients with various cardiac conditions.

02 Respiratory Medicine

Advanced research in severe asthma management, exploring new biological therapies and treatment optimization strategies. Studies focus on comparing different therapeutic approaches for patients with eosinophilic phenotypes.

  • Asthma Biologics Evaluation
  • Treatment Duration Assessment
  • Therapeutic Monitoring

Investigations aim to improve long-term outcomes for patients with severe respiratory conditions.

03 Inflammatory Conditions

Comprehensive studies examining treatments for ulcerative colitis, sarcoidosis, and inflammatory eye conditions. Research includes innovative monitoring approaches and medication optimization.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Treatment Strategies

Focus on improving patient outcomes through targeted therapies and personalized treatment approaches.

04 Rheumatology and Joint Health

Investigating innovative treatments for knee osteoarthritis and gout, particularly in patients with complex medical conditions. Studies explore new interventional procedures and medication alternatives.

  • Joint Disease Management
  • Pain Control Studies
  • Minimally Invasive Treatments

Research aims to enhance quality of life for patients with chronic joint conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.